Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The firm offers customized assay development and manufacturing services for POC tests and digital reader platforms. The company also directly develops, manufactures, and commercializes Lumos-branded POC tests that target infectious and inflammatory diseases. Its Products offering is based on developing and commercializing its own suite of POC diagnostic products which are primarily focused on the diagnosis and management of infectious diseases. These include FebriDx, a POC test for detecting and differentiating viral and bacterial respiratory infections, and ViraDx, a rapid point-of-care diagnostic product that simultaneously tests for acute respiratory infections caused by the COVID-19, influenza A, and influenza B viruses. The company manages the full development program for POC assays.
Who is the CEO of Lumos Diagnostics Holdings Limited?
Mr. Doug Ward is the Chief Executive Officer of Lumos Diagnostics Holdings Limited, joining the firm since 2022.
What is the price performance of LUMOS DIAGNOSTICS HLDGS LTD stock?
The current price of LUMOS DIAGNOSTICS HLDGS LTD is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Lumos Diagnostics Holdings Limited?
Lumos Diagnostics Holdings Limited belongs to Health Care industry and the sector is Health Care
What is Lumos Diagnostics Holdings Limited market cap?
Lumos Diagnostics Holdings Limited's current market cap is $NaN
Is Lumos Diagnostics Holdings Limited a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Lumos Diagnostics Holdings Limited, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell